607 related articles for article (PubMed ID: 17724741)
1. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
2. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
3. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
4. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
5. [Pharmacovigilance: a case of phantom ships and Russian roulette].
Stricker BH
Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
[TBL] [Abstract][Full Text] [Related]
6. The Food and Drug Administration's Drug Safety Oversight Board: an evolving paradigm for clinical input on drug safety topics.
Grandinetti CA; Osborne SF
Clin Pharmacol Ther; 2010 Aug; 88(2):269-74. PubMed ID: 20531466
[No Abstract] [Full Text] [Related]
7. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
[TBL] [Abstract][Full Text] [Related]
8. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.
Swain E; Morgan S; Brewster W; Kauser S
Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):232-7. PubMed ID: 20033909
[TBL] [Abstract][Full Text] [Related]
9. An underrecognized challenge in evaluating postmarketing drug safety.
Roden DM
Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
[No Abstract] [Full Text] [Related]
10. Bad medicine: prescription drugs, preemption, and the potential for a no-fault fix.
Smirniotopoulos A
Rev Law Soc Change; 2012; 35(4):793-862. PubMed ID: 22363960
[TBL] [Abstract][Full Text] [Related]
11. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
12. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
13. National adverse drug reaction reporting. 1984-1989.
Faich GA
Arch Intern Med; 1991 Aug; 151(8):1645-7. PubMed ID: 1872669
[TBL] [Abstract][Full Text] [Related]
14. Opening Pandora's pillbox: using modern information tools to improve drug safety.
Gottlieb S
Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
[TBL] [Abstract][Full Text] [Related]
15. Ensuring the optimal safety of licensed vaccines: a perspective of the vaccine research, development, and manufacturing companies.
Kanesa-thasan N; Shaw A; Stoddard JJ; Vernon TM
Pediatrics; 2011 May; 127 Suppl 1():S16-22. PubMed ID: 21502248
[TBL] [Abstract][Full Text] [Related]
16. Active drug safety surveillance: a tool to improve public health.
Platt R; Madre L; Reynolds R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1175-82. PubMed ID: 18823068
[TBL] [Abstract][Full Text] [Related]
17. Drug safety special: chasing shadows.
Frantz S
Nature; 2005 Mar; 434(7033):557-8. PubMed ID: 15800592
[No Abstract] [Full Text] [Related]
18. Estimating post-marketing exposure to pharmaceutical products using ex-factory distribution data.
Telfair T; Mohan AK; Shahani S; Klincewicz S; Atsma WJ; Thomas A; Fife D
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):749-53. PubMed ID: 16758501
[TBL] [Abstract][Full Text] [Related]
19. Strategy for surveillance of adverse drug events.
Bright RA
Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
[No Abstract] [Full Text] [Related]
20. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
Ferranti J; Horvath MM; Cozart H; Whitehurst J; Eckstrand J
Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]